pre-miRNA Information | |
---|---|
pre-miRNA | hsa-mir-361 |
Genomic Coordinates | chrX: 85903636 - 85903707 |
Synonyms | MIRN361, hsa-mir-361, MIR361 |
Description | Homo sapiens miR-361 stem-loop |
Comment | None |
RNA Secondary Structure | |
Associated Diseases |
Mature miRNA Information | ||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mature miRNA | hsa-miR-361-5p | |||||||||||||||||||||
Sequence | 6| UUAUCAGAAUCUCCAGGGGUAC |27 | |||||||||||||||||||||
Evidence | Experimental | |||||||||||||||||||||
Experiments | Cloned | |||||||||||||||||||||
Editing Events in miRNAs |
|
|||||||||||||||||||||
SNPs in miRNA |
|
|||||||||||||||||||||
Putative Targets |
miRNA Expression profile | |
---|---|
Human miRNA Tissue Atlas | |
miRNAs in Extracellular Vesicles |
|
Circulating MicroRNA Expression Profiling |
Gene Information | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Symbol | U2SURP | ||||||||||||||||||||
Synonyms | SR140, fSAPa | ||||||||||||||||||||
Description | U2 snRNP associated SURP domain containing | ||||||||||||||||||||
Transcript | NM_001080415 | ||||||||||||||||||||
Expression | |||||||||||||||||||||
Putative miRNA Targets on U2SURP | |||||||||||||||||||||
3'UTR of U2SURP (miRNA target sites are highlighted) |
>U2SURP|NM_001080415|3'UTR 1 CGTAAATTTTTAAGATGCTGTCACTTATTGGAAATGCGATTTGTTTTGTGCCTGAACGGTCTGTTTTTTAAAAAAACAAA 81 AAATCAAATGAAAGAGCATTCCTGGGGTTTTTTGTTTGTTTGTGTATGCATGTGTAAACTCATGAGCAACTGCATCTGTA 161 GATCTGTCATTGTTTTATATTGTGTAAATTACTTTCATTGTGGCTATTTCTCAAGATGAAATTTTTATTGTTCTAATGGA 241 TTTCATCAGAAATGTGTATAATGGATCTGCTGACAGTAGTAGTATTTTGTTTTAGGATGTTGTGACTTAGCAAAAATAAT 321 ACAGATGTCTTCCCCCCTTTTGTAGCTTTGACAATTTGAATTAGATTTCAAATAAAATCTGAACAGAAAACTATAATGTT 401 GTTTTTTTGCCCCACCGGTGATATTAAGTCCCTTAAAGTCCTACTGAGTTTCACACTACTGTTGTGCTTCTTATACCTGA 481 TGCACTTTATAAGCCCCAGTGTTCAAGTAGCTTAAGTTTTATATTTACTAAGATGACTATCCAAATTAAGGGACCTGAGA 561 CTCCTATTTGGTGGTTTGCTAACCATTTGCTTTTGATAAGTTTCTCTTGGGTAATACTAATACCCAGATATCAAAGACTA 641 GGTAGATATGGCATGGCGTTTTGTTAGTGGAATGCCTGGCTAAAACATTTTTTTCACAGAAGCAATATGATTTCCATACA 721 TCCAACCCATGTTCTGAGCAACTACTTACTTTTAGGGGGAAATTAAATATCTTTTCATTTCCTCTTCTATTATGAAAGAA 801 GTTTATTTGTAAAACAAATTTTCTAACAAGGTTTGGCCATAGAATTCTCTTGTATGATCGTTGACCTTTTATAATCTTCT 881 GTAGGCTATCTTTCAAACACTGGCATCAGAATATTTTTTATAAGTTTGTGTTTAAACAGCTTAGTTGGTCCCCCCCCACT 961 CCCAAGAGACTTGGGTTTAGTTATAGCTTTAAGTAAAATTTAAAAATAAAATGTTTTTCAGGAAACTTCGTATCTAATGG 1041 TTTGTAAATTCAAGGTGCAAAAAGTTGATTTAAACCATTTGCAGAGTTGAACTCTATTATGAAAATAAATTTGCTACGGT 1121 ATGAGGAAGAAATAAAACTTGTGTAATGTTGGTCATAATACTGCTATAAATATAATAAAGGGTTATGTAGAATTGAACTG 1201 ACACTATTATTTGTGAATCTTGATTTCAGTTTTTTATGTAGGCACTTCATACACTGGTTTGATGGGTTTTTTTTTTCCTC 1281 CCTAAAAGAGAAAGTAGAAAACTATTCTAACAATGGATTATTTTGATTTAGCTTGCTTTTTAAAAAAATCTTTTCAACTT 1361 GTTTTACTTAATCTTGCCTAGTCACAAAATAAGATGTGCACCCATGGTTTGGAGAGTTCCTATATTAGCTGAGCAGTGAG 1441 ATACACTATTTCCAAACGGTGCACACCTACAGTAGCTTTGGAAATGAGCCAATCACTGTTTTACTTAATGGTTCTTATCA 1521 GCATGCAAATATTGCTTGAAAGTTATTTCCTTATTCACTGTTTTGTTAGTCCATTTTGTTAGGAAACATTAATTCCTAAA 1601 AATTTGTTCAGAATAATTAAAAGTGAACATTTGGTGCTGATACTCAAAAACCTACAAATGTAGCCATTTAAAAAGTAACA 1681 TGTTTTTCTCCCCTGCTCATTGCCTGGGAGAATGGAATTTTATATAACTACCTTTCTTTGCAAAAATAACGGTCGTGTCG 1761 AGTTGGTGGTGATTTTGGCATTCCATCTTGCACTGGTTTCTAGTATAGGCTTAGAAATAATTGGTCAGGTAATAATCTTT 1841 CCAGTCAAGTTGCAAGGGATGCTTATTTCTCTTCAAAAAAAGACATCCTGCGGGATTGAGTAGAAAATTTTAGGTCAGTT 1921 TTGGGTGCTTATTTGTAATATTTTTCCTACTACATTGGAGTTTAGCAGTTCTTTTTTTCTGGATCCAGATACAAGTGTCA 2001 TGGTTTATCTTACAGTGGGTGAAACTGACTTTCTTTTGGTTGGGTGGGTGAGGATTTCTTAGGCCTGATAGAATATATAT 2081 TCTGTGAAGTTTGTTAATGTACATATTAGATTGTATTGGATTTTTTTTTCTTGAATTGCAAATGGTATTATTAGATAGGT 2161 TATTTCCAGTTTTACTTCATGACAAATTACCTAGAGTAAACCTACTTAATACTCCCATGGATTCTATGAAAGTTTAATGG 2241 GATCAGAAATTGGTGACTTATAAGGGGGAAGATATTCTACCATATTTTTATAATAGCTTATTATTCATGTTTCTTGTCTG 2321 AAGGACACTCAAGTTACAGAGCAAAATTTCTATAGGTTGACTAGAATGTTCATAAGCATGGTCTTCCAGTTGCAGGAAAG 2401 ATCATGTTCTATCTGTGGACACTTACTGTCCTCTACCACAGCTACGTGCCAGAGTTGTTTTCCACAGTTCTTATAAAGGG 2481 CATGACTTAGGCTCTTTACCCTCCAACTTAATGTTTATACACAGGGATTGTTTACTAGGTTAATGACATTTAACTCCCCT 2561 CTCTTCTGTAGGTGAGAGAAAATAAGTAAGTCTTGATCTGTTTCTTACCAAAGAGAGACAGACCTATGATGGAAAATGAT 2641 CACGTCTCTGAATTTTTTCTTTAACGTTATAGTTCCTTATTACAGATAGTAAGCATATGGGAATTTCTGAGCTATAACAT 2721 GTTGAGAAGTTAGAAATTAAAACTAACACAACAAAAGGCGCTGAATCAAAAGATCTTTGCTTTTATTTGGCTCAGAATGT 2801 TTTTGGCTTTTCTGCTAAAGATGGCAGAAATTACTCTACACAGACCTGATTTTTCTTTATTGCAGACCATTCTTGTGGGC 2881 TTACCCTGAGACTTTTATCCCAATTAGTGAATCTTGGAGGGAATACTTGCTTATTTATGACTTAGGTATTTCCCCCCAAA 2961 CTTTAATATTCTTGAGCACTTGAAAATACTTTTGAGAAATTTTAACTGTGATTAAATTTAGGTTTATTAGAAATATTCTG 3041 TACACATTTGCCTCCATGGTGGCGTAAGTTCTGAAAAATTATATGACCGTGACAATAGTTTATCATCATCATTATTGTTA 3121 TTCAAAATAAGGGTAAATAAATCTCTGTATTGCCAAAGTGACTTAAACTGTTCTGATGACCACACAGTGTGATTTCTTTA 3201 GCAGAGAAAGTTGGTTTTAAAAATAAATAGTACCACTTTTCTAAGACTGTACAGTTTACAAATAAGGTTTTTTTCTTTGT 3281 TGTTTTCCTCTTCTATTAAGTTTTAGTGAAAAGCCTAATTACAGAAAATTGTGCAGATACTAGTGAAGATACTAGTATAA 3361 GTTTAAAGGAACACGTGACTGTAAAATCTCACATTTACAAAGTGCTTGATCTCTTCATATTTCACACGCATGTTTTAGAA 3441 TAGATTTTAGGGAGTGTTTAATTCATTATCCTTTTGACTTAAAATTTTTGTTACCAACTTCCTAGGACTTAGATAATATA 3521 TAAATAAGTACAAATCCCAGGGGAAGTGTTGTGATGCTAGACTAAAAGGTGGGAATGTGCTGCTGTTCCGTGAGCCTTGT 3601 TCCATTGTTGAAAATTTGATGCCTCAGTGTTTATTCAGTACCACCTCATGGAGCTTCAATGTAAATGGATTATATGTATA 3681 ATTGGTAATTTGTATAGTTTTGTAGATTGTAGATTAAATGCACTCATCATGTCACATGTAATTGTGCTTGGAGTATTTGT 3761 GTTTTATTCTTTTACTTCAACGGGTTCTTGTCTGTTACATCTCTGGTGATTTGAAATATCAGGAAAGACAGTTTGTCAGA 3841 AATGAGAATAATATAGTTGAAATCAGTTGGGCTAAAATATTCTACAGCAAGACAATTTCTTTTGGGTGAACTGATTCTAT 3921 AATTTACTTACTTTTAATGTAAGGATTAGATTTATTGTTGAGCTGCTTTCCAGATCAGACTGTCACTTTATAGTTTTTCT 4001 ACATAAAGATTATATAGTTGCAAACAAAGGTTGTGAAATTTCCCTTTTGTTGTTTTTGACTTTTAATTAATAAAAGTACA 4081 TTGTTTTCATAGCAAACTTAGACTGTCCATGTAATTTTCTCCATATTGTTTTTCCGATGCAAGCCCAGTTAATAATTAGT 4161 TTTTTAGCAGCTTTCTCTCAAGTGAAATAAGTGATGTGACATGTTTATCAGTTATGGCTAAAATGTTACACTTTACATGT 4241 TTAAACTATAATCATATGTTTTCATGCTAGATGGT Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||
miRNA-target interactions (Predicted by miRanda) |
|
||||||||||||||||||||
DRVs in gene 3'UTRs | |||||||||||||||||||||
SNPs in gene 3'UTRs |
Experimental Support 1 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Article |
- Hafner M; Landthaler M; Burger L; Khorshid et al. - Cell, 2010
RNA transcripts are subject to posttranscriptional gene regulation involving hundreds of RNA-binding proteins (RBPs) and microRNA-containing ribonucleoprotein complexes (miRNPs) expressed in a cell-type dependent fashion. We developed a cell-based crosslinking approach to determine at high resolution and transcriptome-wide the binding sites of cellular RBPs and miRNPs. The crosslinked sites are revealed by thymidine to cytidine transitions in the cDNAs prepared from immunopurified RNPs of 4-thiouridine-treated cells. We determined the binding sites and regulatory consequences for several intensely studied RBPs and miRNPs, including PUM2, QKI, IGF2BP1-3, AGO/EIF2C1-4 and TNRC6A-C. Our study revealed that these factors bind thousands of sites containing defined sequence motifs and have distinct preferences for exonic versus intronic or coding versus untranslated transcript regions. The precise mapping of binding sites across the transcriptome will be critical to the interpretation of the rapidly emerging data on genetic variation between individuals and how these variations contribute to complex genetic diseases.
LinkOut: [PMID: 20371350]
|
MiRNA-Target Expression Profile | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
MiRNA-Target Expression Profile (TCGA) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
152 hsa-miR-361-5p Target Genes:
Functional analysis:
ID | Target | Description | Validation methods | |||||||||
Strong evidence | Less strong evidence | |||||||||||
MIRT004447 | VEGFA | vascular endothelial growth factor A | 4 | 3 | ||||||||
MIRT020074 | U2SURP | U2 snRNP associated SURP domain containing | 1 | 1 | ||||||||
MIRT020075 | RPUSD4 | RNA pseudouridylate synthase domain containing 4 | 1 | 1 | ||||||||
MIRT020076 | DEPDC1B | DEP domain containing 1B | 1 | 1 | ||||||||
MIRT020077 | CENPQ | centromere protein Q | 1 | 1 | ||||||||
MIRT020078 | EAPP | E2F associated phosphoprotein | 1 | 1 | ||||||||
MIRT020079 | CD46 | CD46 molecule | 1 | 1 | ||||||||
MIRT020080 | EDC3 | enhancer of mRNA decapping 3 | 1 | 1 | ||||||||
MIRT020081 | LHFPL4 | LHFPL tetraspan subfamily member 4 | 1 | 1 | ||||||||
MIRT020082 | ZNF92 | zinc finger protein 92 | 1 | 1 | ||||||||
MIRT020083 | ZNF776 | zinc finger protein 776 | 1 | 1 | ||||||||
MIRT020084 | ARF4 | ADP ribosylation factor 4 | 1 | 1 | ||||||||
MIRT020085 | WDR36 | WD repeat domain 36 | 1 | 1 | ||||||||
MIRT020086 | ZMYND11 | zinc finger MYND-type containing 11 | 1 | 1 | ||||||||
MIRT020087 | FGFR1OP2 | FGFR1 oncogene partner 2 | 1 | 1 | ||||||||
MIRT020088 | RAB8B | RAB8B, member RAS oncogene family | 1 | 1 | ||||||||
MIRT020089 | TNRC6A | trinucleotide repeat containing 6A | 1 | 1 | ||||||||
MIRT020090 | CEBPG | CCAAT/enhancer binding protein gamma | 1 | 1 | ||||||||
MIRT020091 | KLHL28 | kelch like family member 28 | 1 | 1 | ||||||||
MIRT020092 | G3BP2 | G3BP stress granule assembly factor 2 | 1 | 1 | ||||||||
MIRT020093 | SRSF3 | serine and arginine rich splicing factor 3 | 2 | 3 | ||||||||
MIRT020094 | RNF141 | ring finger protein 141 | 1 | 1 | ||||||||
MIRT020095 | YOD1 | YOD1 deubiquitinase | 1 | 1 | ||||||||
MIRT020096 | DUSP3 | dual specificity phosphatase 3 | 2 | 3 | ||||||||
MIRT020097 | NCEH1 | neutral cholesterol ester hydrolase 1 | 1 | 1 | ||||||||
MIRT020098 | GTF2E1 | general transcription factor IIE subunit 1 | 1 | 1 | ||||||||
MIRT020099 | PHACTR4 | phosphatase and actin regulator 4 | 1 | 1 | ||||||||
MIRT020100 | ZC3H12C | zinc finger CCCH-type containing 12C | 1 | 1 | ||||||||
MIRT020101 | ARCN1 | archain 1 | 1 | 1 | ||||||||
MIRT020102 | RNF4 | ring finger protein 4 | 1 | 1 | ||||||||
MIRT020103 | CPOX | coproporphyrinogen oxidase | 1 | 1 | ||||||||
MIRT020104 | CDC123 | cell division cycle 123 | 1 | 1 | ||||||||
MIRT044053 | SLC30A5 | solute carrier family 30 member 5 | 1 | 1 | ||||||||
MIRT044054 | ATP6V1A | ATPase H+ transporting V1 subunit A | 1 | 1 | ||||||||
MIRT044055 | TMEM62 | transmembrane protein 62 | 1 | 1 | ||||||||
MIRT044056 | ZNF554 | zinc finger protein 554 | 1 | 1 | ||||||||
MIRT044057 | MAGEF1 | MAGE family member F1 | 1 | 1 | ||||||||
MIRT044058 | GRK6 | G protein-coupled receptor kinase 6 | 1 | 1 | ||||||||
MIRT044059 | DDX23 | DEAD-box helicase 23 | 1 | 1 | ||||||||
MIRT044060 | BSG | basigin (Ok blood group) | 1 | 1 | ||||||||
MIRT044061 | VCPIP1 | valosin containing protein interacting protein 1 | 1 | 1 | ||||||||
MIRT044062 | VCP | valosin containing protein | 1 | 1 | ||||||||
MIRT044063 | PTCD3 | pentatricopeptide repeat domain 3 | 1 | 1 | ||||||||
MIRT044064 | SLC25A5 | solute carrier family 25 member 5 | 1 | 1 | ||||||||
MIRT044065 | ZNF207 | zinc finger protein 207 | 1 | 1 | ||||||||
MIRT044066 | EGFL7 | EGF like domain multiple 7 | 1 | 1 | ||||||||
MIRT044067 | SETD1A | SET domain containing 1A | 1 | 1 | ||||||||
MIRT044068 | KIAA1549L | KIAA1549 like | 1 | 1 | ||||||||
MIRT044069 | COX1 | cytochrome c oxidase subunit I | 1 | 1 | ||||||||
MIRT044070 | SON | SON DNA binding protein | 1 | 1 | ||||||||
MIRT044071 | HUWE1 | HECT, UBA and WWE domain containing 1, E3 ubiquitin protein ligase | 1 | 1 | ||||||||
MIRT044072 | PPA1 | pyrophosphatase (inorganic) 1 | 1 | 1 | ||||||||
MIRT044073 | DCTN1 | dynactin subunit 1 | 1 | 1 | ||||||||
MIRT044074 | ERAL1 | Era like 12S mitochondrial rRNA chaperone 1 | 1 | 1 | ||||||||
MIRT044075 | CYCS | cytochrome c, somatic | 1 | 1 | ||||||||
MIRT044076 | ACTG1 | actin gamma 1 | 1 | 1 | ||||||||
MIRT044077 | RANBP17 | RAN binding protein 17 | 1 | 1 | ||||||||
MIRT044078 | QTRTD1 | queuine tRNA-ribosyltransferase accessory subunit 2 | 1 | 1 | ||||||||
MIRT044079 | NCOA6 | nuclear receptor coactivator 6 | 1 | 1 | ||||||||
MIRT044080 | ACLY | ATP citrate lyase | 1 | 1 | ||||||||
MIRT044081 | LNPEP | leucyl and cystinyl aminopeptidase | 1 | 1 | ||||||||
MIRT044082 | C14orf80 | tubulin epsilon and delta complex 1 | 1 | 1 | ||||||||
MIRT044083 | VBP1 | VHL binding protein 1 | 1 | 1 | ||||||||
MIRT044084 | OGDH | oxoglutarate dehydrogenase | 1 | 1 | ||||||||
MIRT044085 | ASH1L | ASH1 like histone lysine methyltransferase | 1 | 1 | ||||||||
MIRT044086 | MDC1 | mediator of DNA damage checkpoint 1 | 1 | 1 | ||||||||
MIRT044087 | RPS2 | ribosomal protein S2 | 1 | 1 | ||||||||
MIRT044088 | UCK2 | uridine-cytidine kinase 2 | 1 | 1 | ||||||||
MIRT044089 | PRPF8 | pre-mRNA processing factor 8 | 1 | 1 | ||||||||
MIRT044090 | GSPT1 | G1 to S phase transition 1 | 1 | 1 | ||||||||
MIRT044091 | CALCOCO2 | calcium binding and coiled-coil domain 2 | 1 | 1 | ||||||||
MIRT044092 | USP22 | ubiquitin specific peptidase 22 | 1 | 1 | ||||||||
MIRT044093 | HSPA1B | heat shock protein family A (Hsp70) member 1B | 1 | 1 | ||||||||
MIRT044094 | CNOT2 | CCR4-NOT transcription complex subunit 2 | 1 | 1 | ||||||||
MIRT044095 | SMG1 | SMG1, nonsense mediated mRNA decay associated PI3K related kinase | 1 | 1 | ||||||||
MIRT044096 | WBP2 | WW domain binding protein 2 | 1 | 1 | ||||||||
MIRT044097 | ZBTB33 | zinc finger and BTB domain containing 33 | 1 | 1 | ||||||||
MIRT044098 | GPC6 | glypican 6 | 1 | 1 | ||||||||
MIRT044099 | PRKCSH | protein kinase C substrate 80K-H | 1 | 1 | ||||||||
MIRT044100 | EIF3C | eukaryotic translation initiation factor 3 subunit C | 1 | 1 | ||||||||
MIRT044101 | SUPT16H | SPT16 homolog, facilitates chromatin remodeling subunit | 1 | 1 | ||||||||
MIRT044102 | DOCK6 | dedicator of cytokinesis 6 | 1 | 1 | ||||||||
MIRT044103 | ECD | ecdysoneless cell cycle regulator | 1 | 1 | ||||||||
MIRT044104 | EPHA4 | EPH receptor A4 | 1 | 1 | ||||||||
MIRT044105 | EIF4A1 | eukaryotic translation initiation factor 4A1 | 1 | 1 | ||||||||
MIRT044106 | PSMD2 | proteasome 26S subunit, non-ATPase 2 | 1 | 1 | ||||||||
MIRT044107 | RAE1 | ribonucleic acid export 1 | 1 | 1 | ||||||||
MIRT044108 | RAVER1 | ribonucleoprotein, PTB binding 1 | 1 | 1 | ||||||||
MIRT044109 | TP53BP1 | tumor protein p53 binding protein 1 | 1 | 1 | ||||||||
MIRT044110 | COPS7A | COP9 signalosome subunit 7A | 1 | 1 | ||||||||
MIRT044111 | GTDC2 | protein O-linked mannose N-acetylglucosaminyltransferase 2 (beta 1,4-) | 1 | 1 | ||||||||
MIRT044112 | CDK2 | cyclin dependent kinase 2 | 1 | 1 | ||||||||
MIRT044113 | NOP2 | NOP2 nucleolar protein | 1 | 1 | ||||||||
MIRT112226 | MDM4 | MDM4, p53 regulator | 2 | 2 | ||||||||
MIRT127737 | ENTPD1 | ectonucleoside triphosphate diphosphohydrolase 1 | 2 | 2 | ||||||||
MIRT226898 | RAD23B | RAD23 homolog B, nucleotide excision repair protein | 2 | 2 | ||||||||
MIRT235959 | BACH1 | BTB domain and CNC homolog 1 | 2 | 2 | ||||||||
MIRT241215 | MTPAP | mitochondrial poly(A) polymerase | 2 | 4 | ||||||||
MIRT243416 | ZMAT3 | zinc finger matrin-type 3 | 2 | 2 | ||||||||
MIRT294566 | ZNF460 | zinc finger protein 460 | 2 | 4 | ||||||||
MIRT321041 | RAC1 | Rac family small GTPase 1 | 2 | 4 | ||||||||
MIRT437351 | STAT6 | signal transducer and activator of transcription 6 | 3 | 1 | ||||||||
MIRT438339 | SND1 | staphylococcal nuclease and tudor domain containing 1 | 3 | 1 | ||||||||
MIRT444521 | WWTR1 | WW domain containing transcription regulator 1 | 2 | 2 | ||||||||
MIRT447699 | ERP44 | endoplasmic reticulum protein 44 | 2 | 2 | ||||||||
MIRT464962 | TWIST1 | twist family bHLH transcription factor 1 | 2 | 2 | ||||||||
MIRT468193 | SGK1 | serum/glucocorticoid regulated kinase 1 | 2 | 2 | ||||||||
MIRT473767 | MAP3K9 | mitogen-activated protein kinase kinase kinase 9 | 2 | 2 | ||||||||
MIRT482630 | AAR2 | AAR2 splicing factor homolog | 2 | 2 | ||||||||
MIRT484150 | CENPN | centromere protein N | 2 | 2 | ||||||||
MIRT490457 | PROSER2 | proline and serine rich 2 | 2 | 2 | ||||||||
MIRT493066 | MTCH1 | mitochondrial carrier 1 | 2 | 2 | ||||||||
MIRT493579 | HSP90AA1 | heat shock protein 90 alpha family class A member 1 | 2 | 8 | ||||||||
MIRT506495 | MSANTD4 | Myb/SANT DNA binding domain containing 4 with coiled-coils | 2 | 2 | ||||||||
MIRT514833 | ZNF154 | zinc finger protein 154 | 2 | 6 | ||||||||
MIRT519028 | KYNU | kynureninase | 2 | 6 | ||||||||
MIRT521750 | PPIL1 | peptidylprolyl isomerase like 1 | 2 | 4 | ||||||||
MIRT522899 | KCNJ3 | potassium voltage-gated channel subfamily J member 3 | 2 | 4 | ||||||||
MIRT527368 | MGARP | mitochondria localized glutamic acid rich protein | 2 | 2 | ||||||||
MIRT530684 | C8orf46 | chromosome 8 open reading frame 46 | 2 | 2 | ||||||||
MIRT531397 | TMEM18 | transmembrane protein 18 | 2 | 2 | ||||||||
MIRT533163 | WIPF2 | WAS/WASL interacting protein family member 2 | 2 | 2 | ||||||||
MIRT534579 | RPL28 | ribosomal protein L28 | 2 | 2 | ||||||||
MIRT545955 | ZBTB10 | zinc finger and BTB domain containing 10 | 2 | 2 | ||||||||
MIRT553282 | TSR1 | TSR1, ribosome maturation factor | 2 | 2 | ||||||||
MIRT553531 | TMEM185B | transmembrane protein 185B | 2 | 4 | ||||||||
MIRT555601 | PIP4K2C | phosphatidylinositol-5-phosphate 4-kinase type 2 gamma | 2 | 2 | ||||||||
MIRT556005 | NAPG | NSF attachment protein gamma | 2 | 2 | ||||||||
MIRT556738 | KLHL15 | kelch like family member 15 | 2 | 2 | ||||||||
MIRT556971 | HSPA4L | heat shock protein family A (Hsp70) member 4 like | 2 | 2 | ||||||||
MIRT558904 | CCDC58 | coiled-coil domain containing 58 | 2 | 2 | ||||||||
MIRT559220 | BLMH | bleomycin hydrolase | 2 | 2 | ||||||||
MIRT559821 | SLPI | secretory leukocyte peptidase inhibitor | 2 | 2 | ||||||||
MIRT562671 | AKT3 | AKT serine/threonine kinase 3 | 2 | 2 | ||||||||
MIRT564793 | ZBTB7A | zinc finger and BTB domain containing 7A | 2 | 2 | ||||||||
MIRT564827 | ZBTB18 | zinc finger and BTB domain containing 18 | 2 | 2 | ||||||||
MIRT570505 | TFIP11 | tuftelin interacting protein 11 | 2 | 2 | ||||||||
MIRT571381 | JKAMP | JNK1/MAPK8-associated membrane protein | 2 | 2 | ||||||||
MIRT572562 | AFF1 | AF4/FMR2 family member 1 | 2 | 2 | ||||||||
MIRT610398 | AR | androgen receptor | 2 | 2 | ||||||||
MIRT641614 | DEFB118 | defensin beta 118 | 2 | 2 | ||||||||
MIRT642143 | CHORDC1 | cysteine and histidine rich domain containing 1 | 2 | 2 | ||||||||
MIRT643846 | EPGN | epithelial mitogen | 2 | 4 | ||||||||
MIRT651751 | VEGFB | vascular endothelial growth factor B | 2 | 2 | ||||||||
MIRT657353 | HNRNPA2B1 | heterogeneous nuclear ribonucleoprotein A2/B1 | 2 | 2 | ||||||||
MIRT662436 | RALGAPA1 | Ral GTPase activating protein catalytic alpha subunit 1 | 2 | 2 | ||||||||
MIRT700990 | PDE3A | phosphodiesterase 3A | 2 | 2 | ||||||||
MIRT707393 | DCAF4L1 | DDB1 and CUL4 associated factor 4 like 1 | 2 | 2 | ||||||||
MIRT712064 | XRCC5 | X-ray repair cross complementing 5 | 2 | 2 | ||||||||
MIRT721145 | PLCL1 | phospholipase C like 1 (inactive) | 2 | 2 | ||||||||
MIRT724466 | SMAD2 | SMAD family member 2 | 2 | 2 | ||||||||
MIRT731374 | CXCR6 | C-X-C motif chemokine receptor 6 | 1 | 1 |
miRNA-Drug Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
miRNA-Drug Resistance Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|